Basics CRISPR Therapeutics AG CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. IPO Date: October 19, 2016 Sector: Healthcare Industry: Biotech Market Cap: $6.73B Activated in VL: True Average Daily Range Avg Daily Range: $1.62 | 2.80% Avg Daily Range (30 D): $2.20 | 3.30% Avg Daily Range (90 D): $1.63 | 2.73% Institutional Daily Volume Avg Daily Volume: 1.18M Avg Daily Volume (30 D): 2.4M Avg Daily Volume (90 D): 2.66M Trade Size Avg Trade Size (Sh.): 63 Avg Trade Size (Sh.) (30 D): 52 Avg Trade Size (Sh.) (90 D): 57 Institutional Trades Total Inst.Trades: 5,786 Avg Inst. Trade: $2.95M Avg Inst. Trade (30 D): $5.15M Avg Inst. Trade (90 D): $4.75M Avg Inst. Trade Volume: .05M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $5.42M Avg Closing Trade (30 D): $16.14M Avg Closing Trade (90 D): $15.81M Avg Closing Volume: 84.62K     News Oct 8, 2025 @ 2:15 PM Healthcare Stocks Are Rising: Here Are 2 With Even... Source: Prosper Junior Bakiny Oct 8, 2025 @ 2:00 PM Gene Therapy Market Size to Worth USD 58.87 Billio... Source: Towards Healthcare Oct 1, 2025 @ 9:10 AM Got $200? 2 Healthcare Stocks to Buy and Hold Fore... Source: Adria Cimino Sep 18, 2025 @ 12:45 PM Global Cell Therapy Market Size Expected to Reach ... Source: Prnewswire Sep 9, 2025 @ 8:00 PM CRISPR Therapeutics to Present Late-Breaking Data ... Source: Crispr Therapeutics Financials   TTM Q2 2025 Q1 2025 Basic EPS $-5.41 $-2.4 $-1.58 Diluted EPS $-5.41 $-2.4 $-1.58 Revenue $ 38.05M $ .89M $ .87M Gross Profit $ $ $ Net Income / Loss $ -467.8M $ -208.55M $ -136M Operating Income / Loss $ -552.47M $ -229.32M $ -148.42M Cost of Revenue $ $ $ Net Cash Flow $ -290.96M $ -41.65M $ -63.11M PE Ratio